Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Jahn, Beate, Rochau, Ursula, Kurzthaler, Christina, Hubalek, Michael, Miksad, Rebecca, Sroczynski, Gaby, Paulden, Mike, Bundo, Marvin, Stenehjem, David, Brixner, Diana, Krahn, Murray, Siebert, Uwe
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2017
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5644100/
https://ncbi.nlm.nih.gov/pubmed/29037213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3603-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge